Results 111 to 120 of about 3,014 (182)

Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor. [PDF]

Pharmacoeconomics
Fernández Coves A, Scholte M, Emerson J, Wolff R, Abu-Zahra T, Chen J, McDermott K, Armstrong N, Joore M, Witlox W.   +9 more
europepmc   +1 more source

Postmarketing Cases of Erdafitinib-Associated Skeletal Growth Toxicity Events in Pediatric Patients. [PDF]

Pediatr Blood Cancer
Nadeau Nguyen M, Dores GM, Nayernama A, Jones SC.   +3 more
europepmc   +1 more source

RingKin: portraying the vast macrocyclic chemical universe surrounding kinase drugs. [PDF]

Chem Sci
Diao Y, Hu F, Jiang W, Hu Y, Ma S, Wu D, Tong L, Xiang S, Chen C, Li Z, Shen Z, Zhao Z, Xu Y, Li J, Li H.   +14 more
europepmc   +1 more source

Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity. [PDF]

Mol Cancer Ther
Starrett JH, Allen EL, Neal M, Iyer S, Ye Q, Hudkins RL, Degaonkar V, Lihou C, Swanson RV, Boni V, Fuentes-Antrás J, Pobel C, Loriot Y, Zalutskaya A, Goluboff E.   +14 more
europepmc   +1 more source

FGFR3 Alterations and Nectin-4 Expression as Therapeutic Biomarkers in Bladder Cancer: A Systematic Review and Single-Arm Meta-Analysis. [PDF]

Int J Mol Sci
Antonov P, Raycheva G, Eshrefov D, Belov A, Uchikov P, Ivanov A, Popov V, Pacini M, Zucchi A, Nicolini A, Penchev P.   +10 more
europepmc   +1 more source

The rising cost of litigation for urological tumors in the Brazilian Public Health System: an analysis of e-NatJus technical notes (2020-2026). [PDF]

Int Braz J Urol
Korkes F, Pedrotti C, Tocci F.
europepmc   +1 more source

Identification of natural FGFR3 inhibitor for glioma using integrated computational and microRNA regulatory analysis. [PDF]

Sci Rep
Javaid S, Ali N, Shahid S, Majeed MN.
europepmc   +1 more source

Current Landscape and Evolving Role of Targeted Agents in Urothelial Carcinoma. [PDF]

Cancers (Basel)
Sammarco E, Pellino A, Bona E, Farnesi A, Biasco E, Caparello C, Marini A, Stasi I, Musettini G, Barbara C, De Maio E, Coltelli L, Cupini S, Allegrini G.   +13 more
europepmc   +1 more source

Chilblain lupus erythematosus associated with erdafitinib therapy in a patient with metastatic bladder cancer

JAAD Case Reports
Amanda Truong, MD, PhD, Jennifer Liu, MD, PhD, Catherine Ni, MD, Sharona Yashar, MD   +3 more
doaj   +1 more source